The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...

New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...

The most important features of inhalation affecting drug deposition are inhaled volume, flow rate, and any breathholding pause maintained at the end of inspiration. The greater the inhaled volume ...

Inhaled insulin was noninferior to usual care in glycemic control outcomes after 17 weeks among patients with type 1 diabetes.

After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...

Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).

The U.S. Food and Drug Administration has approved inhalable insulin to help patients control their blood sugar levels. ManKind Corporation's Afrezza is a fast-acting form of insulin intended for ...

‘A breath of fresh air for #diabetes_management! Inhaled #insulin, #Afrezza, is now available in #India, thanks to #Cipla. #diabetes’ The company noted that Afrezza will start working in as ...

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control, according to a study published online Dec.

Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with ...